Prostate Cell News Volume 11.18 | May 22 2020

TOP STORY

2,4-Dienoyl-CoA Reductase Regulates Lipid Homeostasis in Treatment-Resistant Prostate Cancer

Scientists performed a comprehensive unbiased characterization of LNCaP cells chronically exposed to multiple androgen receptor inhibitors. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

Enzyme-Mediated Depletion of Serum L-Met Abrogates Prostate Cancer Growth via Multiple Mechanisms without Evidence of Systemic Toxicity

Scientists describe the development of an engineered human enzyme that reduced systemic L-methionine (L-Met) levels and significantly inhibited the growth of multiple prostate cancer allografts/xenografts without weight loss or toxicity. [Proc Natl Acad Sci USA] Full Article

TGF-β1 Promotes Epithelial-to-Mesenchymal Transition and Stemness of Prostate Cancer Cells by Inducing PCBP1 Degradation and Alternative Splicing of CD44

The authors report a novel mechanism of CD44 alternative splicing induced by TGF-β1 and its connection to enhanced epithelial-to-mesenchymal transition and stemness in human prostate cancer cells. [Cell Mol Life Sci] Abstract

GLUT1 Is an AR Target Contributing to Tumor Growth and Glycolysis in Castration-Resistant and Enzalutamide-Resistant Prostate Cancers

GLUT1 inhibition significantly suppressed cell growth, glycolysis and tumor volume in a xenograft model both in castration-resistant prostate cancer and enzalutamide-resistant prostate cancer. [Cancer Lett] Abstract

Cross-Resistance among Next Generation Anti-Androgen Drugs through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer

The authors showed that enzalutamide and abiraterone resistant prostate cancer cells were further cross-resistant to apalutamide and darolutamide. [Mol Cancer Ther] Abstract

Prostate Epithelial RON Signaling Promotes M2 Macrophage Activation to Drive Prostate Tumor Growth and Progression

The authors showed that loss of RON selectively in prostate epithelial cells led to significantly reduced prostate tumor growth and metastasis and was associated with increased intratumor infiltration of macrophages. [Mol Cancer Res] Abstract

Cyclopentadienyl Ruthenium(II) Carbosilane Metallodendrimers as a Promising Treatment against Advanced Prostate Cancer

These metallodendrimers possessed potent and selective anticancer activity in vitro in a panel of tumor cell lines. [Eur J Med Chem] Abstract

Protein Kinase CK2 Impact on Intracellular Calcium Homeostasis in Prostate Cancer

Prostate cancer cells were treated with the CK2 small molecule inhibitors 4,5,6,7-tetrabrombenzotriazole and CX-4945 followed by analysis of Ca²⁺ levels in various cellular compartments over time. [Mol Cell Biochem] Abstract

Identification of a Natural Compound, Sesamin, as a Novel TRPM8 Antagonist with Inhibitory Effects on Prostate Adenocarcinoma

The cytotoxicity and specificity of sesamin to TRPM8 were tested in HEK293/TRPM8 cells. The effect of sesamin on cell proliferation in prostate adenocarcinoma cell lines was assessed. [Fitoterapia] Abstract | Graphical Abstract

Synthesis and Biological Activity of 5-Aryliden-2-Thiohydantoin S-Aryl Derivatives

Selected by molecular docking, compounds were tested on androgen receptor activation, and p53-Mdm2 regulation, and A549, MCF7, VA13, HEK293T, PC3, LnCAP cell lines for cytotoxicity. [Bioorg Chem] Abstract | Graphical Abstract

Long Non-Coding RNA FAM66C Is Associated with Clinical Progression and Promotes Cell Proliferation by Inhibiting Proteasome Pathway in Prostate Cancer

Real-time PCR showed that FAM66C was highly expressed in prostate cancer cells, and knockdown FAM66C by siRNAs resulted in significant inhibition of cell growth. [Cell Biochem Funct] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Signaling through Estrogen Receptors Modulates Long Non-Coding RNAs in Prostate Cancer

The authors summarize recent pieces of evidence about lncRNAs NEAT1, H19, MALAT1, and HOTAIR, in estrogen signaling, emphasizing their role in prostate cancer progression and the acquisition of a castration-resistant phenotype. [Mol Cell Endocrinol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Poseida Therapeutics Announces Dosing of First Patient in Phase I Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer

Poseida Therapeutics, Inc. announced the first patient has been dosed in its Phase I clinical trial evaluating P-PSMA-101, its autologous CAR-T therapeutic candidate, in metastatic castration-resistant prostate cancer. [Poseida Therapeutics, Inc.] Press Release

Myriad Receives FDA Approval of BRACAnalysis CDx^® as a Companion Diagnostic for Lynparza^® in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer

Myriad Genetics, Inc. announced that the FDA approved the BRACAnalysis CDx^® test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer who are eligible for treatment with Lynparza^®. [Myriad Genetics, Inc.] Press Release

Will Trump White House Tear Down Journal Paywalls? Many Anxiously Await a Decision

Scientific publishers, universities, librarians, and open-access advocates are waiting anxiously to see whether the Trump administration will end a long-standing policy and require that every scholarly article produced with US funding be made immediately free to all. [ScienceInsider] Editorial

Are Women Publishing Less during the Pandemic? Here’s What the Data Say

Early analyses suggest that female academics are posting fewer preprints and starting fewer research projects than their male peers. [Nature News] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Prostate Cancer Research (The Vita-Salute San Raffaele University)

Postdoctoral Fellow – Cancer Metabolism Research (Augusta University)

Postdoctoral Fellowship – Molecular Mechanisms in Prostate Cancer (Cleveland Clinic)

Doctoral Student – Prostate Cancer (Karolinska Institutet)

Associate Professor – Prostate Disease Research (Uniformed Services University of the Health Sciences)

Postdoctoral Position – Chaperone-Mediated Autophagy Research in Cancer (Karolinska Institutet)

Assistant Professor – Cell Cycle and Cancer Biology (Oklahoma Medical Research Foundation)

Associate Professor – Cancer Biology (University of Cincinnati)

Postdoctoral Position – Prostate Cancer (University of Washington)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.